Company profile for Sapience Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sapience Therapeutics is focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. Our drug candidates target protein-protein interactions (“PPIs”) that are responsible for either making the cells cancerous or dampening the immune response against tumors. These targets are considered ‘undruggable’ becaus...
Sapience Therapeutics is focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. Our drug candidates target protein-protein interactions (“PPIs”) that are responsible for either making the cells cancerous or dampening the immune response against tumors. These targets are considered ‘undruggable’ because they are PPIs that reside inside of the cell, making them difficult to treat with small molecule drugs such as chemotherapies (which are incapable of disrupting PPIs) or newer biologic-based drugs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
500 Mamaroneck Ave Suite 320 Harrison, NY 10528
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/sapience-therapeutics-to-present-multiple-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025-302411365.html

PR NEWSWIRE
26 Mar 2025

https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-st316-phase-1-dose-escalation-data-at-the-2025-american-society-of-clinical-oncology-asco-gastrointestinal-gi-cancers-symposium-302360732.html

PR NEWSWIRE
27 Jan 2025

https://www.prnewswire.com/news-releases/sapience-therapeutics-receives-fda-orphan-drug-designation-for-st316-a-first-in-class--catenin-antagonist-for-the-treatment-of-familial-adenomatous-polyposis-fap-302335639.html

PR NEWSWIRE
19 Dec 2024

https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-multiple-presentations-at-the-society-for-immunotherapy-of-cancers-sitc-39th-annual-meeting-302269680.html

PR NEWSWIRE
08 Oct 2024

https://www.prnewswire.com/news-releases/sapience-therapeutics-enrolls-first-patient-in-phase-2-study-of-st316-a-first-in-class--catenin-antagonist-in-colorectal-cancer-302263343.html

PR NEWSWIRE
01 Oct 2024

https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-positive-clinical-and-biomarker-data-from-st101-phase-2-study-in-gbm-at-asco-2024-in-oral-presentation-302161146.html

PR NEWSWIRE
01 Jun 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty